[go: up one dir, main page]

CN111302977B - Purification method of pharmaceutical grade guanidine hydrochloride - Google Patents

Purification method of pharmaceutical grade guanidine hydrochloride Download PDF

Info

Publication number
CN111302977B
CN111302977B CN202010192916.7A CN202010192916A CN111302977B CN 111302977 B CN111302977 B CN 111302977B CN 202010192916 A CN202010192916 A CN 202010192916A CN 111302977 B CN111302977 B CN 111302977B
Authority
CN
China
Prior art keywords
guanidine hydrochloride
ultrasonic
crude
pharmaceutical grade
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010192916.7A
Other languages
Chinese (zh)
Other versions
CN111302977A (en
Inventor
刘永超
钱炜雯
韩菊泉
吴景渊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunan Wugan Pharmaceutical Co ltd
Original Assignee
Hunan Wugan Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunan Wugan Pharmaceutical Co ltd filed Critical Hunan Wugan Pharmaceutical Co ltd
Priority to CN202010192916.7A priority Critical patent/CN111302977B/en
Publication of CN111302977A publication Critical patent/CN111302977A/en
Application granted granted Critical
Publication of CN111302977B publication Critical patent/CN111302977B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/06Purification or separation of guanidine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/10Process efficiency

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明公开了一种医药级盐酸胍的纯化方法,它包括以下步骤:(a)将盐酸胍粗胍加入水中进行搅拌混合,随后泵入粗滤器中除去杂质,得盐酸胍粗胍水溶液;所述盐酸胍粗胍与所述水的质量比为1.5~3:1;(b)将所述盐酸胍粗胍水溶液泵入超声波结晶系统,进行连续、循环处理得盐酸胍清液,并诱导析出细微杂质;所述超声波结晶系统的控制参数为:温度0℃~120℃、水力学停留时间0.5h~2h和超声波电源的频率10KHz~20KHz;(c)将所述盐酸胍清液泵入过滤器,除去细微杂质晶粒;随后再泵入脱色器,除去溶解在所述盐酸胍清液中的微量氰胺类杂质,得精制盐酸胍溶液;(d)将所述精制盐酸胍溶液泵入结晶器,进行结晶纯化;分离晶体,经烘干得医药级盐酸胍。极大地提高了生产效率并减少了生产周期。

Figure 202010192916

The invention discloses a method for purifying pharmaceutical grade guanidine hydrochloride, which comprises the following steps: (a) adding crude guanidine hydrochloride into water for stirring and mixing, and then pumping it into a coarse filter to remove impurities to obtain an aqueous solution of crude guanidine hydrochloride; The mass ratio of the crude guanidine hydrochloride to the water is 1.5 to 3:1; (b) the crude guanidine hydrochloride aqueous solution is pumped into the ultrasonic crystallization system, and the guanidine hydrochloride clear liquid is obtained by continuous and cyclic processing, and is induced to precipitate Fine impurities; the control parameters of the ultrasonic crystallization system are: temperature 0 ℃ ~ 120 ℃, hydraulic retention time 0.5h ~ 2h and frequency of ultrasonic power source 10KHz ~ 20KHz; (c) the guanidine hydrochloride clear liquid is pumped into the filter Then, it is pumped into the decolorizer to remove the trace amount of cyanamide impurities dissolved in the guanidine hydrochloride clear liquid to obtain a refined guanidine hydrochloride solution; (d) the purified guanidine hydrochloride solution is pumped into the Crystallizer, crystallization and purification; separation of crystals, drying to obtain pharmaceutical grade guanidine hydrochloride. Greatly improve production efficiency and reduce production cycle.

Figure 202010192916

Description

一种医药级盐酸胍的纯化方法A kind of purification method of pharmaceutical grade guanidine hydrochloride

技术领域technical field

本发明属于有机物的提纯技术领域,涉及一种医药级盐酸胍的纯化方法,具体涉及一种医药级盐酸胍超声波诱导纯化方法。The invention belongs to the technical field of purification of organic matter, relates to a purification method of pharmaceutical grade guanidine hydrochloride, and in particular relates to a method for ultrasonically induced purification of pharmaceutical grade guanidine hydrochloride.

背景技术Background technique

医药级盐酸胍主要在蛋白质及细胞生物学领域具有广泛的应用;由于其应用领域的特殊要求,产品对杂质的要求非常高,除常规的含量、熔点、PH、不溶物、水份等常规技术参数外,最苛刻的技术指标还体现在紫外光吸光度上:紫外吸光度260μm≤0.04,280μm≤0.02。Pharmaceutical grade guanidine hydrochloride has a wide range of applications mainly in the fields of protein and cell biology; due to the special requirements of its application field, the product has very high requirements for impurities, in addition to conventional technologies such as content, melting point, PH, insoluble matter, and moisture content In addition to the parameters, the most demanding technical indicators are also reflected in the UV absorbance: UV absorbance 260μm≤0.04, 280μm≤0.02.

目前,盐酸胍的纯化主要是采用固体盐酸胍粗胍溶解到水溶液中,利用杂质与产品在水溶液中的溶解度差异,结晶析出固体杂质,分离盐酸胍的工艺。由于该工艺中杂质的种类较多,主要有未反应完的原料,还有副反应生成的氰胺类多聚物,各种杂质的含量不同,且溶解度差距较大,为了保证各种杂质最大可能的去除,低浓度的杂质需要较长的结晶成核时间,从而导致盐酸胍纯化的周期较长,产能严重受限。因此,开发医药级盐酸胍高处理量除杂工艺具有重要的意义。At present, the purification of guanidine hydrochloride mainly adopts the process of dissolving solid guanidine hydrochloride crude guanidine hydrochloride into an aqueous solution, utilizing the solubility difference between impurities and products in the aqueous solution, crystallization and precipitation of solid impurities, and separating guanidine hydrochloride. Since there are many types of impurities in this process, there are mainly unreacted raw materials and cyanamide polymers generated by side reactions. The content of various impurities is different, and the solubility gap is large. In order to ensure the maximum amount of various impurities The possible removal of impurities with low concentration requires a long crystallization nucleation time, which leads to a long purification cycle of guanidine hydrochloride and a serious limitation of production capacity. Therefore, it is of great significance to develop a high-throughput impurity removal process for pharmaceutical grade guanidine hydrochloride.

发明内容SUMMARY OF THE INVENTION

本发明目的是为了克服现有技术的不足而提供一种医药级盐酸胍的纯化方法。The purpose of the present invention is to provide a purification method of pharmaceutical grade guanidine hydrochloride in order to overcome the deficiencies of the prior art.

为达到上述目的,本发明采用的技术方案是:一种医药级盐酸胍的纯化方法,它包括以下步骤:In order to achieve the above object, the technical scheme adopted in the present invention is: a purification method of pharmaceutical grade guanidine hydrochloride, which comprises the following steps:

(a)将盐酸胍粗胍加入水中进行搅拌混合,随后泵入粗滤器中除去杂质,得盐酸胍粗胍水溶液;所述盐酸胍粗胍与所述水的质量比为1.5~3:1;(a) adding crude guanidine hydrochloride to water for stirring and mixing, then pumping into a coarse filter to remove impurities to obtain an aqueous solution of crude guanidine hydrochloride; the mass ratio of crude guanidine hydrochloride to the water is 1.5 to 3:1;

(b)将所述盐酸胍粗胍水溶液泵入超声波结晶系统,进行连续、循环处理得盐酸胍清液,并诱导析出细微杂质;所述超声波结晶系统的控制参数为:温度0℃~120℃、水力学停留时间0.5h~2h和超声波电源的频率10KHz~20KHz;(b) pumping the crude guanidine hydrochloride aqueous solution into an ultrasonic crystallization system, performing continuous and cyclic processing to obtain clear guanidine hydrochloride liquid, and inducing the precipitation of fine impurities; the control parameters of the ultrasonic crystallization system are: temperature 0 ℃~120 ℃ , hydraulic retention time 0.5h ~ 2h and frequency of ultrasonic power source 10KHz ~ 20KHz;

(c)将所述盐酸胍清液泵入过滤器,除去细微杂质晶粒;随后再泵入脱色器,除去溶解在所述盐酸胍清液中的微量氰胺类杂质,得精制盐酸胍溶液;(c) pumping the guanidine hydrochloride clear liquid into a filter to remove the fine impurity crystal grains; then pumping into a decolorizer to remove the trace cyanamide impurities dissolved in the guanidine hydrochloride clear liquid to obtain a refined guanidine hydrochloride solution ;

(d)将所述精制盐酸胍溶液泵入结晶器,进行结晶纯化;分离晶体,经烘干得医药级盐酸胍。(d) pumping the purified guanidine hydrochloride solution into a crystallizer for crystallization and purification; separating crystals and drying to obtain pharmaceutical grade guanidine hydrochloride.

优化地,步骤(a)中,在20℃~120℃的温度下将盐酸胍粗胍和水进行搅拌混合,搅拌时间为0.5h~1h。Preferably, in step (a), the crude guanidine hydrochloride and water are stirred and mixed at a temperature of 20°C to 120°C, and the stirring time is 0.5h to 1h.

优化地,步骤(b)中,所述超声波结晶系统带有供所述盐酸胍粗胍水溶液进行循环的内循环系统。Optimally, in step (b), the ultrasonic crystallization system has an internal circulation system for circulating the crude guanidine hydrochloride aqueous solution.

优化地,步骤(c)中,所述过滤器为精密过滤器。Optimally, in step (c), the filter is a precision filter.

进一步地,步骤(c)中,所述脱色器的控制参数为:温度50℃~90℃、压力常压~0.2MPa 和水力学停留时间0.5h~1h。Further, in step (c), the control parameters of the decolorizer are: temperature of 50°C to 90°C, normal pressure to 0.2MPa, and hydraulic residence time of 0.5h to 1h.

由于上述技术方案运用,本发明与现有技术相比具有下列优点:本发明医药级盐酸胍的纯化方法,通过控制盐酸胍粗胍与水的混合比例,并精确控制超声波结晶系统的工艺参数,这样能够将医药级盐酸胍的产能提高7~10倍,生产周期由20~30天减少到3天左右,极大地提高了生产效率并减少了生产周期。Due to the application of the above-mentioned technical solutions, the present invention has the following advantages compared with the prior art: the purification method of pharmaceutical grade guanidine hydrochloride of the present invention, by controlling the mixing ratio of crude guanidine hydrochloride and water, and accurately controlling the process parameters of the ultrasonic crystallization system, In this way, the production capacity of pharmaceutical grade guanidine hydrochloride can be increased by 7 to 10 times, and the production cycle can be reduced from 20 to 30 days to about 3 days, which greatly improves the production efficiency and reduces the production cycle.

附图说明Description of drawings

图1为本发明医药级盐酸胍的纯化方法工艺流程图;Fig. 1 is the process flow diagram of the purification method of pharmaceutical grade guanidine hydrochloride of the present invention;

图2为本发明医药级盐酸胍的纯化设备图。Fig. 2 is the purification equipment diagram of pharmaceutical grade guanidine hydrochloride of the present invention.

具体实施方式Detailed ways

本发明医药级盐酸胍的纯化方法,如图1所示,它包括以下步骤:(a)将盐酸胍粗胍加入水中进行搅拌混合,随后泵入粗滤器中除去杂质,得盐酸胍粗胍水溶液;所述盐酸胍粗胍与所述水的质量比为1.5~3:1;(b)将所述盐酸胍粗胍水溶液泵入超声波结晶系统,进行连续、循环处理得盐酸胍清液,并诱导析出细微杂质;所述超声波结晶系统的控制参数为:温度0℃~120℃、水力学停留时间0.5h~2h和超声波电源的频率10KHz~20KHz;(c)将所述盐酸胍清液泵入过滤器,除去细微杂质晶粒;随后再泵入脱色器,除去溶解在所述盐酸胍清液中的微量氰胺类杂质,得精制盐酸胍溶液;(d)将所述精制盐酸胍溶液泵入结晶器,进行结晶纯化;分离晶体,经烘干得医药级盐酸胍。通过控制盐酸胍粗胍与水的混合比例,并精确控制超声波结晶系统的工艺参数,这样能够将医药级盐酸胍的产能提高7~10倍,生产周期由 20~30天减少到3天左右,极大地提高了生产效率并减少了生产周期。The purification method of pharmaceutical grade guanidine hydrochloride of the present invention, as shown in Figure 1, comprises the following steps: (a) adding crude guanidine hydrochloride into water for stirring and mixing, then pumping into a coarse filter to remove impurities to obtain an aqueous solution of crude guanidine hydrochloride The mass ratio of the crude guanidine hydrochloride to the water is 1.5 to 3:1; (b) the crude guanidine hydrochloride aqueous solution is pumped into the ultrasonic crystallization system, and continuous and cyclic processing are carried out to obtain the guanidine hydrochloride clear liquid, and Induce the precipitation of fine impurities; the control parameters of the ultrasonic crystallization system are: temperature 0 ℃ ~ 120 ℃, hydraulic retention time 0.5h ~ 2h and frequency of ultrasonic power source 10KHz ~ 20KHz; (c) the guanidine hydrochloride clear liquid pump into a filter to remove fine impurity crystal grains; then pump into a decolorizer to remove trace cyanamide impurities dissolved in the guanidine hydrochloride clear liquid to obtain a refined guanidine hydrochloride solution; (d) the refined guanidine hydrochloride solution Pump into a crystallizer for crystallization and purification; separate crystals and dry to obtain pharmaceutical grade guanidine hydrochloride. By controlling the mixing ratio of crude guanidine hydrochloride and water, and accurately controlling the process parameters of the ultrasonic crystallization system, the production capacity of pharmaceutical grade guanidine hydrochloride can be increased by 7 to 10 times, and the production cycle can be reduced from 20 to 30 days to about 3 days. Greatly improve production efficiency and reduce production cycle.

步骤(a)中,优选在20℃~120℃的温度下将盐酸胍粗胍和水进行搅拌混合,搅拌时间为0.5h~1h。步骤(b)中,所述超声波结晶系统带有供所述盐酸胍粗胍水溶液进行循环的内循环系统,有利于提高细微杂质晶粒的析出效果。步骤(c)中,所述过滤器为精密过滤器,提高细微杂质晶粒的过滤效果。步骤(c)中,所述脱色器的控制参数为:温度50℃~90℃、压力常压~0.2MPa和水力学停留时间0.5h~1h,以提高脱色效果。In step (a), the crude guanidine hydrochloride and water are preferably stirred and mixed at a temperature of 20°C to 120°C, and the stirring time is 0.5 h to 1 h. In step (b), the ultrasonic crystallization system has an internal circulation system for circulating the crude guanidine hydrochloride aqueous solution, which is beneficial to improve the precipitation effect of fine impurity crystal grains. In step (c), the filter is a precision filter, which improves the filtering effect of fine impurity grains. In step (c), the control parameters of the decolorizer are: temperature of 50°C to 90°C, normal pressure to 0.2MPa, and hydraulic residence time of 0.5h to 1h, so as to improve the decolorization effect.

下面将结合对本发明优选实施方案进行详细说明。The preferred embodiments of the present invention will be described in detail below.

实施例1Example 1

本实施例提供一种医药级盐酸胍的纯化方法,它包括以下步骤:The present embodiment provides a purification method of pharmaceutical grade guanidine hydrochloride, which comprises the following steps:

(a)在常压下,将500g水加入混合器,再加入1200g盐酸胍粗胍,于60℃搅拌30min,搅拌均匀后泵入粗滤器,除去机械杂质和未完全溶解的固体颗粒杂质,得盐酸胍粗胍水溶液;(a) under normal pressure, add 500 g of water into the mixer, then add 1200 g of crude guanidine hydrochloride, stir at 60 ° C for 30 min, stir evenly and then pump into a coarse filter to remove mechanical impurities and incompletely dissolved solid particles to obtain Guanidine hydrochloride crude guanidine aqueous solution;

(b)将经过粗滤器除去机械杂质和未完全溶解固体颗粒杂质而得到的盐酸胍粗胍水溶液泵入超声波结晶系统进行连续、循环处理得盐酸胍清液以诱导析出细微杂质(超声波结晶系统采用连续处理式,其带内循环系统以将盐酸胍粗胍水溶液进行循环处理),得盐酸胍清液;超声波结晶系统的操作控制参数为:温度60℃、压力常压、水力学停留时间60min和超声波电源的频率20KHz;上述超声波结晶系统采用自研的设备,如图2所示,包括静置组件1、超声波诱导结晶组件2和压滤机3。超声波诱导结晶组件2包括用于盐酸胍粗胍水溶液进液的进液管道22、与进液管道22一端相连通且通过管道相串联的多个超声波结晶器21(本实施例中为三个,具体数量可以根据实际需要选择)以及一端与超声波结晶器21(最下游的那个,其根据盐酸胍粗胍水溶液的流通方向定义)相连通的出液管道23;静置组件1包括静置罐体10、一端与静置罐体10上端相连通的清液出液管11、一端与静置罐体10下端连通的杂质富集液出液管12、安装在静置罐体10内且一端与出液管道23另一端相连通的导液管13 以及安装在静置罐体10内且与导液管13相配合的锥形隔板组合体14(锥形隔板组合体14 设置在导液管13另一端的下方而与其相通,包括中心管以及安装在中心管侧壁上且与其相通的锥形隔板,锥形隔板由下向上依次层叠设置并向下延伸,以将超声波诱导结晶组件的出液经缓冲后导入静置罐体10内,使得杂质能够逐渐向静置罐体10的底部富集;此时静置罐体 10内的盐酸胍清液液面上升而经由清液出液管11溢出或排出);压滤机3通过管道分别与杂质富集液出液管12的另一端和进液管道22中部相连接,用于对杂质富集液进行压滤后将压滤液重新导入进液管道22进行循环处理,而压滤产生的滤饼可委外处理;(b) The crude guanidine hydrochloride aqueous solution obtained by removing mechanical impurities and incompletely dissolved solid particle impurities through a coarse filter is pumped into an ultrasonic crystallization system for continuous and cyclic treatment to obtain guanidine hydrochloride clear liquid to induce the precipitation of fine impurities (the ultrasonic crystallization system adopts Continuous treatment type, which has an internal circulation system to recycle the crude guanidine hydrochloride aqueous solution) to obtain guanidine hydrochloride clear liquid; the operation control parameters of the ultrasonic crystallization system are: temperature 60 ° C, pressure and normal pressure, hydraulic residence time 60min and The frequency of the ultrasonic power source is 20KHz; the above-mentioned ultrasonic crystallization system adopts self-developed equipment, as shown in Figure 2, including a static component 1, an ultrasonic-induced crystallization component 2 and a filter press 3. The ultrasonic-induced crystallization assembly 2 includes a liquid inlet pipe 22 for feeding the crude guanidine hydrochloride aqueous solution, and a plurality of ultrasonic crystallizers 21 (three in this embodiment, three in this embodiment, one end of the liquid inlet pipe 22 and a plurality of ultrasonic crystallizers 21 connected in series through the pipes. The specific number can be selected according to actual needs) and a liquid outlet pipe 23 with one end connected to the ultrasonic crystallizer 21 (the most downstream one, which is defined according to the flow direction of the crude guanidine hydrochloride aqueous solution); the static component 1 includes a static tank 10. The clear liquid outlet pipe 11 whose one end communicates with the upper end of the stationary tank 10, and the impurity enrichment liquid outlet pipe 12 whose one end is communicated with the lower end of the stationary tank 10, is installed in the stationary tank 10 and has one end connected to the lower end of the stationary tank 10. The liquid conduit 13 connected to the other end of the liquid outlet pipe 23 and the conical separator assembly 14 installed in the static tank 10 and matched with the liquid conduit 13 (the conical separator assembly 14 is arranged in the liquid conduit). The bottom of the other end of the tube 13 communicates with it, including a central tube and a conical baffle installed on the side wall of the central tube and communicated with it. The effluent of the component is buffered and then introduced into the stationary tank 10, so that impurities can be gradually enriched to the bottom of the stationary tank 10; at this time, the level of the guanidine hydrochloride clear liquid in the stationary tank 10 rises and passes The liquid outlet pipe 11 overflows or discharges); the filter press 3 is respectively connected with the other end of the impurity-enriched liquid outlet pipe 12 and the middle of the liquid inlet pipe 22 through the pipeline, and is used to filter the impurity-enriched liquid after pressure filtration. The filtrate is re-introduced into the liquid inlet pipeline 22 for recycling, and the filter cake produced by the pressure filtration can be outsourced;

(c)将经过超声波结晶系统诱导除杂处理的盐酸胍清液泵入精密过滤器,除去超声波结晶系统未完全去除的细微杂质晶粒;随后将经过精密过滤器的盐酸胍溶液泵入脱色器,以去除溶解在溶液中微量的氰胺类杂质,得精制盐酸胍溶液,脱色器的工艺条件为:温度60℃、压力0.15MPa(G)和水力学停留时间30min;(c) Pump the guanidine hydrochloride clear liquid that has been induced to remove impurities by the ultrasonic crystallization system into the precision filter to remove the fine impurity grains not completely removed by the ultrasonic crystallization system; then pump the guanidine hydrochloride solution that has passed through the precision filter into the decolorizer , in order to remove the trace amount of cyanamide impurities dissolved in the solution to obtain a refined guanidine hydrochloride solution, the process conditions of the decolorizer are: temperature 60 ℃, pressure 0.15MPa (G) and hydraulic residence time 30min;

(d)将精制盐酸胍溶液泵入成品结晶器,进行结晶纯化;分离晶体,经烘干得医药级盐酸胍;收率85%(以粗胍计),纯度99.7%。(d) pumping the purified guanidine hydrochloride solution into the finished product crystallizer for crystallization and purification; separating the crystals and drying to obtain pharmaceutical grade guanidine hydrochloride; the yield is 85% (calculated as crude guanidine) and the purity is 99.7%.

实施例2Example 2

本实施例提供一种医药级盐酸胍的纯化方法,它与实施例1中的基本一致,不同的是:步骤(a)中,将500g水加入混合器,并再加入750g盐酸胍粗胍;收率87%(以粗胍计),纯度99.6%。The present embodiment provides a purification method of pharmaceutical grade guanidine hydrochloride, which is basically the same as that in Example 1, except that: in step (a), 500 g of water is added to the mixer, and then 750 g of crude guanidine hydrochloride is added; The yield was 87% (based on crude guanidine), and the purity was 99.6%.

实施例3Example 3

本实施例提供一种医药级盐酸胍的纯化方法,它与实施例1中的基本一致,不同的是:步骤(a)中,将500g水加入混合器,并再加入1500g盐酸胍粗胍;收率83.5%(以粗胍计),纯度99.8%。The present embodiment provides a purification method for pharmaceutical grade guanidine hydrochloride, which is basically the same as that in Example 1, except that: in step (a), 500 g of water is added to the mixer, and then 1500 g of crude guanidine hydrochloride is added; The yield was 83.5% (calculated as crude guanidine), and the purity was 99.8%.

实施例4Example 4

本实施例提供一种医药级盐酸胍的纯化方法,它与实施例1中的基本一致,不同的是:步骤(a)中,在120℃搅拌45min;收率86%(以粗胍计),纯度99.6%。This example provides a purification method of pharmaceutical grade guanidine hydrochloride, which is basically the same as that in Example 1, except that: in step (a), stirring is performed at 120° C. for 45 min; the yield is 86% (calculated as crude guanidine) , the purity is 99.6%.

实施例5Example 5

本实施例提供一种医药级盐酸胍的纯化方法,它与实施例1中的基本一致,不同的是:步骤(a)中,在20℃搅拌1h;收率84.5%(以粗胍计),纯度99.8%。This example provides a purification method for pharmaceutical grade guanidine hydrochloride, which is basically the same as that in Example 1, except that: in step (a), stirring is performed at 20° C. for 1 h; the yield is 84.5% (calculated as crude guanidine) , 99.8% purity.

实施例6Example 6

本实施例提供一种医药级盐酸胍的纯化方法,它与实施例1中的基本一致,不同的是:步骤(b)中,温度0℃、压力常压、水力学停留时间2h和超声波电源的频率10KHz;收率83.5%(以粗胍计),纯度99.7%。This embodiment provides a purification method of pharmaceutical grade guanidine hydrochloride, which is basically the same as that in Example 1, except that in step (b), the temperature is 0°C, the pressure is normal pressure, the hydraulic residence time is 2h, and the ultrasonic power source is used. The frequency is 10KHz; the yield is 83.5% (calculated as crude guanidine), and the purity is 99.7%.

实施例7Example 7

本实施例提供一种医药级盐酸胍的纯化方法,它与实施例1中的基本一致,不同的是:步骤(b)中,温度120℃、压力常压、水力学停留时间0.5h和超声波电源的频率15KHz;收率84.0%(以粗胍计),纯度99.5%。This embodiment provides a purification method of pharmaceutical grade guanidine hydrochloride, which is basically the same as that in Example 1, except that: in step (b), the temperature is 120° C., the pressure is normal pressure, the hydraulic residence time is 0.5h, and the ultrasonic wave is applied. The frequency of the power source is 15KHz; the yield is 84.0% (calculated as crude guanidine), and the purity is 99.5%.

对比例1Comparative Example 1

本例提供一种医药级盐酸胍的纯化方法,它与实施例1中的基本一致,不同的是:步骤 (a)中,将500g水加入混合器,并再加入2000g盐酸胍粗胍;收率74%(以粗胍计),纯度99.7%。This example provides a purification method for pharmaceutical grade guanidine hydrochloride, which is basically the same as that in Example 1, except that: in step (a), 500 g of water is added to the mixer, and 2000 g of crude guanidine hydrochloride is added; The yield was 74% (calculated as crude guanidine), and the purity was 99.7%.

对比例2Comparative Example 2

本例提供一种医药级盐酸胍的纯化方法,它与实施例1中的基本一致,不同的是:步骤 (b)中,超声波电源的频率50KHz;收率80%(以粗胍计),纯度98.5%。This example provides a purification method of pharmaceutical grade guanidine hydrochloride, which is basically the same as that in Example 1, except that: in step (b), the frequency of the ultrasonic power source is 50KHz; the yield is 80% (calculated as crude guanidine), Purity 98.5%.

对比例3Comparative Example 3

本例提供一种医药级盐酸胍的纯化方法,它与实施例1中的基本一致,不同的是:步骤 (b)中,超声波电源的频率5KHz;收率75%(以粗胍计),纯度98.7%。This example provides a purification method of pharmaceutical grade guanidine hydrochloride, which is basically the same as that in Example 1, except that: in step (b), the frequency of the ultrasonic power source is 5KHz; the yield is 75% (calculated as crude guanidine), Purity 98.7%.

对比例4Comparative Example 4

本例提供一种医药级盐酸胍的纯化方法,它与实施例1中的基本一致,不同的是:步骤 (b)中,超声波结晶系统内温度控制为130℃;收率70%(以粗胍计),纯度98.5%。This example provides a purification method of pharmaceutical grade guanidine hydrochloride, which is basically the same as that in Example 1, except that: in step (b), the temperature in the ultrasonic crystallization system is controlled to be 130°C; guanidine), the purity is 98.5%.

对比例5Comparative Example 5

本例提供一种现有常规的医药级盐酸胍的纯化方法,具体步骤为:This example provides a kind of purification method of existing conventional pharmaceutical grade guanidine hydrochloride, and the concrete steps are:

(a)在常压下,将500g水加入混合器,再加入1200g盐酸胍粗胍,于60℃搅拌30min,搅拌均匀后泵入粗滤器,除去机械杂质和未完全溶解的固体颗粒杂质,得盐酸胍粗胍水溶液;(a) under normal pressure, add 500 g of water into the mixer, then add 1200 g of crude guanidine hydrochloride, stir at 60 ° C for 30 min, stir evenly and then pump into a coarse filter to remove mechanical impurities and incompletely dissolved solid particles to obtain Guanidine hydrochloride crude guanidine aqueous solution;

(b)将经过粗滤器除去机械杂质和未完全溶解固体颗粒杂质而得到的盐酸胍粗胍水溶液泵入除杂沉淀池,在环境温度下静置20天;(b) the crude guanidine hydrochloride aqueous solution obtained by removing mechanical impurities and incompletely dissolving solid particle impurities through the coarse filter is pumped into the impurity-removing sedimentation tank, and left standstill for 20 days at ambient temperature;

(c)将除杂沉淀池的上清液泵入脱色器,得精制盐酸胍溶液,脱色器的工艺条件为:温度60℃、压力0.15MPa(G)和水力学停留时间30min;(c) pump the supernatant of the impurity-removing sedimentation tank into the decolorizer to obtain a purified guanidine hydrochloride solution, and the process conditions of the decolorizer are: temperature 60° C., pressure 0.15MPa (G) and hydraulic residence time 30min;

(d)将精制盐酸胍溶液泵入成品结晶器,进行结晶纯化;分离晶体,经烘干得医药级盐酸胍。(d) pumping the purified guanidine hydrochloride solution into the finished product crystallizer for crystallization and purification; separating the crystals and drying to obtain pharmaceutical grade guanidine hydrochloride.

最终医药级盐酸胍的收率83%(以粗胍计),纯度99.6%(整个纯化方法处理的时间合计约为23天)。The yield of the final pharmaceutical grade guanidine hydrochloride is 83% (calculated as crude guanidine), and the purity is 99.6% (the total processing time of the whole purification method is about 23 days).

上述实施例只为说明本发明的技术构思及特点,其目的在于让熟悉此项技术的人士能够了解本发明的内容并据以实施,并不能以此限制本发明的保护范围,凡根据依据本发明精神实质所作的等效变化或修饰,都应涵盖在本发明的保护范围之内。The above-mentioned embodiments are only to illustrate the technical concept and characteristics of the present invention, and its purpose is to enable those who are familiar with the technology to understand the content of the present invention and implement accordingly, and cannot limit the scope of protection of the present invention with this. Equivalent changes or modifications made in the spirit of the invention shall all be included within the protection scope of the present invention.

Claims (5)

1.一种医药级盐酸胍的纯化方法,其特征在于,它包括以下步骤:1. a purification method of pharmaceutical grade guanidine hydrochloride, is characterized in that, it comprises the following steps: (a)将盐酸胍粗胍加入水中进行搅拌混合,随后泵入粗滤器中除去杂质,得盐酸胍粗胍水溶液;所述盐酸胍粗胍与所述水的质量比为1.5~3:1;(a) adding crude guanidine hydrochloride into water for stirring and mixing, and then pumping it into a coarse filter to remove impurities to obtain an aqueous solution of crude guanidine hydrochloride; the mass ratio of crude guanidine hydrochloride to the water is 1.5 to 3:1; (b)将所述盐酸胍粗胍水溶液泵入超声波结晶系统,进行连续、循环处理得盐酸胍清液,并诱导析出细微杂质;所述超声波结晶系统的控制参数为:温度0℃~120℃、水力学停留时间0.5h~2h和超声波电源的频率10KHz~20KHz;所述超声波结晶系统包括静置组件、超声波诱导结晶组件和压滤机,所述超声波诱导结晶组件包括用于盐酸胍粗胍水溶液进液的进液管道、与进液管道一端相连通且通过管道相串联的多个超声波结晶器以及一端与超声波结晶器相连通的出液管道;所述静置组件包括静置罐体、一端与静置罐体上端相连通的清液出液管、一端与静置罐体下端连通的杂质富集液出液管、安装在静置罐体内且一端与出液管道另一端相连通的导液管以及安装在静置罐体内且与导液管相配合的锥形隔板组合体;所述锥形隔板组合体设置在导液管另一端的下方而与其相通,包括中心管以及安装在中心管侧壁上且与其相通的锥形隔板,所述锥形隔板由下向上依次层叠设置并向下延伸以将超声波诱导结晶组件的出液经缓冲后导入静置罐体内;压滤机通过管道分别与杂质富集液出液管的另一端和进液管道中部相连接;(b) pumping the crude guanidine hydrochloride aqueous solution into an ultrasonic crystallization system, and performing continuous and cyclic processing to obtain guanidine hydrochloride clear liquid, and inducing the precipitation of fine impurities; the control parameters of the ultrasonic crystallization system are: temperature 0 ℃ ~ 120 ℃ , the hydraulic retention time is 0.5h~2h and the frequency of the ultrasonic power source is 10KHz~20KHz; the ultrasonic crystallization system includes a static component, an ultrasonic-induced crystallization component and a filter press, and the ultrasonic-induced crystallization component includes a crude guanidine hydrochloride for guanidine hydrochloride. The liquid inlet pipeline for the aqueous solution inlet, a plurality of ultrasonic crystallizers connected with one end of the liquid inlet pipeline and connected in series through the pipelines, and the liquid outlet pipeline connected with the ultrasonic crystallizer at one end; the static component comprises a static tank, One end of the clear liquid outlet pipe connected with the upper end of the static tank body, one end of the impurity enriched liquid outlet pipe connected with the lower end of the static tank body, installed in the static tank body and one end communicated with the other end of the liquid outlet pipe A catheter and a conical baffle assembly installed in the static tank and matched with the catheter; the conical baffle assembly is arranged below the other end of the catheter and communicated with it, including a central pipe and A conical baffle installed on the side wall of the central tube and communicated with it, the conical baffles are stacked in sequence from bottom to top and extend downward to buffer the effluent of the ultrasonic-induced crystallization assembly into the static tank; The filter press is connected with the other end of the impurity-enriched liquid outlet pipe and the middle of the liquid inlet pipe respectively through pipes; (c)将所述盐酸胍清液泵入过滤器,除去细微杂质晶粒;随后再泵入脱色器,除去溶解在所述盐酸胍清液中的微量氰胺类杂质,得精制盐酸胍溶液;(c) Pump the guanidine hydrochloride clear liquid into a filter to remove fine impurity grains; then pump it into a decolorizer to remove trace cyanamide impurities dissolved in the guanidine hydrochloride clear liquid to obtain a refined guanidine hydrochloride solution ; (d)将所述精制盐酸胍溶液泵入结晶器,进行结晶纯化;分离晶体,经烘干得医药级盐酸胍。(d) pumping the purified guanidine hydrochloride solution into a crystallizer for crystallization and purification; separating the crystals and drying to obtain pharmaceutical grade guanidine hydrochloride. 2.根据权利要求1所述医药级盐酸胍的纯化方法,其特征在于:步骤(a)中,在20℃~120℃的温度下将盐酸胍粗胍和水进行搅拌混合,搅拌时间为0.5h~1h。2. The method for purifying pharmaceutical grade guanidine hydrochloride according to claim 1, characterized in that: in step (a), the crude guanidine hydrochloride and water are stirred and mixed at a temperature of 20°C to 120°C, and the stirring time is 0.5 h~1h. 3.根据权利要求1所述医药级盐酸胍的纯化方法,其特征在于:步骤(b)中,所述超声波结晶系统带有供所述盐酸胍粗胍水溶液进行循环的内循环系统。3 . The method for purifying pharmaceutical grade guanidine hydrochloride according to claim 1 , wherein in step (b), the ultrasonic crystallization system has an internal circulation system for circulating the crude guanidine hydrochloride aqueous solution. 4 . 4.根据权利要求1所述医药级盐酸胍的纯化方法,其特征在于:步骤(c)中,所述过滤器为精密过滤器。4 . The method for purifying pharmaceutical grade guanidine hydrochloride according to claim 1 , wherein in step (c), the filter is a precision filter. 5 . 5.根据权利要求1或4所述医药级盐酸胍的纯化方法,其特征在于:步骤(c)中,所述脱色器的控制参数为:温度50℃~90℃、压力常压~0.2MPa和水力学停留时间0.5h~1h。5. The purification method of pharmaceutical grade guanidine hydrochloride according to claim 1 or 4, characterized in that: in step (c), the control parameters of the decolorizer are: temperature 50 ℃ ~ 90 ℃, pressure and normal pressure ~ 0.2MPa and hydraulic retention time 0.5h~1h.
CN202010192916.7A 2020-03-18 2020-03-18 Purification method of pharmaceutical grade guanidine hydrochloride Active CN111302977B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010192916.7A CN111302977B (en) 2020-03-18 2020-03-18 Purification method of pharmaceutical grade guanidine hydrochloride

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010192916.7A CN111302977B (en) 2020-03-18 2020-03-18 Purification method of pharmaceutical grade guanidine hydrochloride

Publications (2)

Publication Number Publication Date
CN111302977A CN111302977A (en) 2020-06-19
CN111302977B true CN111302977B (en) 2022-05-17

Family

ID=71153510

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010192916.7A Active CN111302977B (en) 2020-03-18 2020-03-18 Purification method of pharmaceutical grade guanidine hydrochloride

Country Status (1)

Country Link
CN (1) CN111302977B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113754567B (en) * 2021-10-13 2024-02-20 宁夏蓝白黑循环科技有限公司 Preparation process of novel refined guanidine carbonate
CN115286538A (en) * 2022-07-12 2022-11-04 烟台三鼎化工有限公司 Antibacterial guanidine hydrochloride efficient crystallization drying process
CN116283830B (en) * 2023-01-08 2025-02-18 湖南吴赣药业有限公司 A kind of preparation method of high-purity 3-morpholinepropanesulfonic acid

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542240A (en) * 1980-02-28 1985-09-17 Degussa Aktiengesellschaft Process for the production of guanidine hydrochloride
CN1385419A (en) * 2002-06-14 2002-12-18 方建文 Process for preparing guanidine hydrochloride
CN103951591A (en) * 2014-05-19 2014-07-30 宁夏贝利特化工有限公司 Production technique of guanidine hydrochloride
CN104860849A (en) * 2015-06-04 2015-08-26 西安近代化学研究所 Continuous crystallization process for preparing nitroguanidine through nitric acid method
CN107721884A (en) * 2017-11-06 2018-02-23 西安近代化学研究所 A kind of nitroguanidine is engineered production technology
CN109232324A (en) * 2018-11-15 2019-01-18 宁夏宁杭循环科技股份有限公司 A kind of novel purification guanidine hydrochloride is synthetically prepared production technology
CN110204461A (en) * 2019-05-15 2019-09-06 西安万德能源化学股份有限公司 The microchannel crystallization processes and device of a kind of nitroguanidine crystal and nitroguanidine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542240A (en) * 1980-02-28 1985-09-17 Degussa Aktiengesellschaft Process for the production of guanidine hydrochloride
CN1385419A (en) * 2002-06-14 2002-12-18 方建文 Process for preparing guanidine hydrochloride
CN103951591A (en) * 2014-05-19 2014-07-30 宁夏贝利特化工有限公司 Production technique of guanidine hydrochloride
CN104860849A (en) * 2015-06-04 2015-08-26 西安近代化学研究所 Continuous crystallization process for preparing nitroguanidine through nitric acid method
CN107721884A (en) * 2017-11-06 2018-02-23 西安近代化学研究所 A kind of nitroguanidine is engineered production technology
CN109232324A (en) * 2018-11-15 2019-01-18 宁夏宁杭循环科技股份有限公司 A kind of novel purification guanidine hydrochloride is synthetically prepared production technology
CN110204461A (en) * 2019-05-15 2019-09-06 西安万德能源化学股份有限公司 The microchannel crystallization processes and device of a kind of nitroguanidine crystal and nitroguanidine

Also Published As

Publication number Publication date
CN111302977A (en) 2020-06-19

Similar Documents

Publication Publication Date Title
CN111302977B (en) Purification method of pharmaceutical grade guanidine hydrochloride
CN101293849B (en) Process for preparing glutamic acid crystallization
CN101085734A (en) Method for purifying itaconic acid fermentation liquor or extracting itaconic acid from itaconic acid mother liquid by film device
CN210419601U (en) Desulfurization waste water resourceful treatment system
CN101182079B (en) Citric acid mother liquor treatment process
CN107915351A (en) System for modular fluidized bed self crystallization handles high rigidity waste water
CN105384230B (en) A kind of cellulose sewage pretreatment device and application
CN101941901A (en) Method for recycling mother solid in PTA-refining wastewater
CN110655547A (en) Adenosine extraction method for reducing content of single related impurities
CN217092171U (en) Device for reducing scale formation of phosphoric acid purification extraction tank
CN201842654U (en) Coking ammonium sulfate finish machining
CN117000166A (en) Multistage tubular guanidinoacetic acid production system and production method
CN111518119B (en) Continuous amoxicillin crystallization process
CN101492369B (en) Separation purification method for benzoic anhydride sour water and production process for allomaleic acid
CN212713097U (en) Low-magnesium desulfurization wastewater zero-discharge treatment system
CN209890387U (en) Treatment system of reverse osmosis concentrated water with high permanent hardness
CN110877941B (en) Ammonia distillation waste liquid recycling system and method by ammonia-alkali method
CN203976932U (en) Succinic acid production unit
CN222057396U (en) Sodium sulfobutyl beta-cyclodextrin purification system
CN207483645U (en) A kind of Pfansteihl crystal production system
CN110306041B (en) Continuous preparation device for rare earth compound precipitate
CN222872150U (en) High conversion rate preparation device of 3,3', 5' -tetramethyl biphenol
CN201670815U (en) A kind of equipment for protein peptide purification
CN204569617U (en) Heavily flocculate carrier waste disposal plant
CN221479922U (en) Production device of sodium glucuronate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A purification method of pharmaceutical grade guanidine hydrochloride

Effective date of registration: 20230112

Granted publication date: 20220517

Pledgee: Agricultural Bank of China Limited Changsha Wangcheng District sub branch

Pledgor: Hunan Wugan Pharmaceutical Co.,Ltd.

Registration number: Y2023430000003

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Granted publication date: 20220517

Pledgee: Agricultural Bank of China Limited Changsha Wangcheng District sub branch

Pledgor: Hunan Wugan Pharmaceutical Co.,Ltd.

Registration number: Y2023430000003

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A purification method for pharmaceutical grade guanidine hydrochloride

Granted publication date: 20220517

Pledgee: Agricultural Bank of China Limited Changsha Wangcheng District sub branch

Pledgor: Hunan Wugan Pharmaceutical Co.,Ltd.

Registration number: Y2024980004057

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Granted publication date: 20220517

Pledgee: Agricultural Bank of China Limited Changsha Wangcheng District sub branch

Pledgor: Hunan Wugan Pharmaceutical Co.,Ltd.

Registration number: Y2024980004057

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A purification method for pharmaceutical grade guanidine hydrochloride

Granted publication date: 20220517

Pledgee: Agricultural Bank of China Limited Changsha Wangcheng District sub branch

Pledgor: Hunan Wugan Pharmaceutical Co.,Ltd.

Registration number: Y2025980002476